Molecular Profiling across 80,000 Patients with Lung Cancer - PubMed

3 hours ago

Biomarker testing is essential for optimal therapeutic management in Non-Small Cell Lung Cancer (NSCLC).
Despite guidelines, many advanced NSCLC patients do not benefit from precision oncology.
Study analyzes actionable genomic alterations across histologic subtypes and clinicodemographic subgroups using 82,328 samples profiled with a single CGP assay.
Actionable genomic alterations were found in 35.1% of cases, with LUAD and adenosquamous histologies having higher rates (45.8% and 40.9%, respectively).
Sarcomatoid histology had the highest frequency of METex14 skipping mutations (9.95% vs. 2.43% in LUAD).
Tumor mutation burden (TMB) ≥10 Mut/Mb varied by histology, with large cell carcinoma showing the highest rate (50.91%).
Patients with actionable genomic alterations typically had low TMB (80.88%).
Significant correlations were found between age and certain mutations/rearrangements (e.g., BRAF/ERBB2, ALK/RET/ROS1, MET amplification).
EGFR actionable mutations and KRAS G12C were more common in females.
Genetic ancestry analyses showed strong correlation for EGFR mutations with South/East Asia and America.
The dataset supports universal molecular testing across all NSCLC subtypes to ensure equitable access to therapeutics.

Hasty Briefsbeta